Mechanisms of Tumor Cell Lysis by Natural Killer Cells

  • Ronald H. Goldfarb
  • Tuomo Timonen
  • Ronald B. Herberman
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 146)


Immune reactivity against malignant cells is well-documented for a number of lymphoid cell types (1). The foremost features of anti-timor immune effector cells appears to be their capacity to recognize and subsequently kill tumor cells. Nevertheless, the mechanism(s) by which effector cells of the immune response mediate tumor cell lysis is largely unknown. The lack of precise knowledge concerning lytic pathways is evident for well studied immune killer cells, such as cytotoxic T Ijrmphocytes, as well as for effector cells that have only recently received intense experimental scrutiny, such as natural killer (NK) cells.


Natural Killer Target Cell Plasminogen Activator Effector Cell Immune Effector Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. (1).
    Herberman, R.B. Immunologic defenses against cancer. In, The pathophysiology of human immunologic disorders, ed. J. J. Twomey, Urban & Schwarzenberg. In Press.Google Scholar
  2. (2).
    Herberman, R.B. Possible roles of natural killer (NK) cells. In, Immunobiology of transplantation, cancer, and pregnancy, ed. P. K. Ray, Plenum Press. In Press.Google Scholar
  3. (3).
    Berke G. Interaction of cytotoxic T lymphocytes and target cells. Prog. Allergy 27:69–133, 1981.Google Scholar
  4. (4).
    Golstein, P., and Smith, E.T. 1977. Mechanism of T-cell mediated cytolysis: the lethal hit stage. Contemp. Top. Immunobiol. 7: 273–300.CrossRefGoogle Scholar
  5. (5).
    Henney, C.S. 1977. T-cell mediated cytolysis: an overview of some current issues. Contemp. Top. Immunobiol. 2:245–272.CrossRefGoogle Scholar
  6. (6).
    Martz, E. 1977. Mechanism of specific tumor-cell lysis by alloiHimune T lymphocytes. Resolution and characterization of discrete steps in the cellular interaction. Contemp. Top. Immunobiol. 7:301–361.PubMedCrossRefGoogle Scholar
  7. (7).
    Goldfarb, R.H., and Herberman R.B. Characteristics of natural killer cells and possible mechansims for their cytotoxic activity. In Ad van. Inflamm. Res., ed. G. Weissman, Raven Press. In Press.Google Scholar
  8. (8).
    Roder, J.C., Kiessling, R., Bibberfeld, P., and Andersson, B. 1978. Traget-effector interaction in the natural killer (NK) cell system. II. The isolation of NK cells and studies on the mechanism of killing. J. Immunol. 121:2509–2517.PubMedGoogle Scholar
  9. (9).
    Roder, J.C., Rosen, A., Fenyo, E.M., and Troy, F.A. 1979. Target-effector interaction in the natural killer cell system: isolation of target structures. Proc. Natl. Acad. Sci. USA, 76:1405–1409.PubMedCrossRefGoogle Scholar
  10. (10).
    Timonen, T., Saksela, E., Ranki, A., and Hayry, P. 1979. Fractionation, morphological and functional characterization of effector cells responsible for human natural killer activity against cell-line targets. Cell. Immunol. 48;133–148.PubMedCrossRefGoogle Scholar
  11. (11).
    Timonen, T., Ortaldo, J.R., and Herberman, R.B. 1981. Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J. Exp. Med., 153:569- 582.PubMedCrossRefGoogle Scholar
  12. (12).
    Goldfarb, R.H., and Herberman, R.B. 1981. Natural killer cell reactivity: Regulatory interactions among phorbol ester, interferon, cholera toxin, and retinoic acid. J. Immunol. 126:2129–2135.PubMedGoogle Scholar
  13. (13).
    Wright, S.C., and Bonavida, B. 1981. Selective lysis of NK- sensitive target cells by a soluble mediator released from murine spleen cells and human peripheral blood lymphocytes. J. Immunol., 126:1516–1521.PubMedGoogle Scholar
  14. (14).
    Goldfarb, R.H. Proteases in tumor invasion and metastasis. In The biology of metastatis., ed. L. A. Liotta and I. R. Hart. In Press.Google Scholar
  15. (15).
    Ferluga, J., Asherson, G.L., and Becker, E.L. 1972. The effect of organophosphorous inhibitors, p-nitrophenol, and cytochalasin B on cytotoxic killing of tumor cells by immune spleen cells and the effects of shaking. Immunol. 23:577–590.Google Scholar
  16. (16).
    Redelman, D., and Hudig, D. 1980. The mechanism of cell mediated cytotoxicity. I. Killing of murine cytotoxic T lymphocytes requires cell surface thiols and activated proteases. J. Immunol., 124:870–878.PubMedGoogle Scholar
  17. (17).
    Hatcher, V.B., Oberman, M.S., Lazarus, G.S., and Grayzel, A.I. 1978. A cytotoxic proteinase isolated from human lymphocytes. J. Immunol. 120:665–670.PubMedGoogle Scholar
  18. (18).
    Ferluga, J., and Allison, A.C. 1974. On the mechanism by which T lymphocytes exert cytotoxic effects. Nature, 250: 673–675.PubMedCrossRefGoogle Scholar
  19. (19).
    Tokes, Z.A. 1976. Estimation of cell surface associated protease activity and its application to lymphocytes. J. Supramolec. Struc., 4:507–513.CrossRefGoogle Scholar
  20. (20).
    Kedar, E., Ortiz de Landazuri, M., and Fahey, J.L. 1974. Enzymatic enhancement of cell-mediated cytotoxicity and antibody-dependent cell cytotoxicity. J. Immunol., 112: 26–36.PubMedGoogle Scholar
  21. (21).
    Matter, A. 1975. A study of proteolysis as a possible mechanism for T cell mediated target cell lysis. Scand. J. Immunol., 4:349–356.Google Scholar
  22. (22).
    Adams, D.O. 1980. Effector mechanisms of cytolytically activated macrophages: I. Secretion of neutral serine proteases and effect of protease inhibitors. J. Immunol., 124: 286–292.PubMedGoogle Scholar
  23. (23).
    Adams, D.O., Kuo-Jang, J., Farb, R., and Pizzo, S.V. 1980. Effector mechanisms of cytolytically activated macrophages. II, Secretion of a cytolytic factor by activated macrophages and its relationship to secreted neutral proteases. J. Immunol., 124:293–300.PubMedGoogle Scholar
  24. (24).
    Piessens, W.F., and Sharma, S.D. 1980. Tumor cell killing by macrophages activated in vitro with lymphocyte mediators. 5. Role of proteases, inhibitors, and substrates. Cellular Immunol., 56:286–291.CrossRefGoogle Scholar
  25. (25).
    Adams, D.O., and Marino, P.A. 1981. Evidence for a multi- step mechanism of cytolysis by BCG-activat;ed macrophages: The interrelationship between the capacity for cytolysis, target binding, and secretion of a cytolytic factor. J. Immunol., 126: 981–987.PubMedGoogle Scholar
  26. (26).
    Unkeless, J.C., Gordon, S., and Reich, E. 1974. Secretion of plasminogen activator by stimulated macrophages. J. Exp. Med., 139:834–850.PubMedCrossRefGoogle Scholar
  27. (27).
    Chapman, H.A., Vavrin, Z., and Hibbs, J.B. 1979. Modulation of plasminogen activator secretion by activated iMicrophages: Influence of serum factors and correlation with tumoricidal potential. Proc. Natl. Acad. Sci. USA, 76:3899–3903.PubMedCrossRefGoogle Scholar
  28. (28).
    Trinchieri, G., and DeMarchi, M. 1976. Antibody dependent cell mediated cytotoxicity in humans. III. Effect of protease inhibitors and shaking. J. Immunol., 116:885–891.PubMedGoogle Scholar
  29. (29).
    Herberman, R.B., editor. 1980. Natural Cell Mediated Immunity Against Tumors. Academic Press, New York.Google Scholar
  30. (30).
    Kishimoto, T., Kikutani, H., Nishizawa, Y., Sakaguchi, N., and Yamamura, Y. 1979. Involvement of anti Ig-activated serine protease in the generation of cytoplasmic factors that are responsible for the transmission of Ig-receptor mediated signals. J. Immunol., 123:1504–1510.PubMedGoogle Scholar
  31. (31).
    Hudig, D., Haverty, T., Fucher, C., Redelman, D., and Mendelsohn, J. 1981. Inhibition of human natural cytotoxicity by macromolecular antiproteases. J. Immunol., 126:1569–1574.PubMedGoogle Scholar
  32. (32).
    Hudig, D., Redelman, D., and Mendelsohn, J. 1980. Inhibition of human natural cytotoxicity by proteinase substrates. Fed. Proc., 469.Google Scholar
  33. (33).
    Lavie, G., Weiss, H., Pick, A.I., and Franklin, E.C. 1980. The role of surface associated proteases in lymphocyte spontaneous cytolytic activity. Fourth Cong. Immunol. Abstracts, 11, 4. 30.Google Scholar
  34. (34).
    Haliotis, R., Roder, J., Klein, M., Ortaldo, J., Fauci, A., and Herberman, R.B. 1980. Chediak-Higashi gene in humans. I. Impairment of natural-killer function. J. Exp. Med., 151:1039–1048.PubMedCrossRefGoogle Scholar
  35. (35).
    Roder, J.C., and Duwe, A.K. 1979. The beige imitation in the mouse selectively impairs natural killer cell function. Nature, 278:451–453.PubMedCrossRefGoogle Scholar
  36. (36).
    Vassali, J., Granelli-Piperno, A., Griscelli, C., and Reich, E. 1978. Specific protease deficiency in polymorphonuclear leukocytes of Chediak-Higashi syndrome and beige mice. J. Exp. Med., 147:1285–1290.CrossRefGoogle Scholar
  37. (37).
    Goldfarb, R.H., and Quigley, J.P. 1978. Production of plasminogen activator by chick embryo fibroblasts: synergistic effect of Rous sarcoma virus transformation and treatment with the tumor promoter phorbol-myristate-acetate. Cancer Res., 38:4601–4608.PubMedGoogle Scholar
  38. (38).
    Maillard, J., Toullet, F., Favreau, C., and Chadenier, F. 1978. Stimulated lymph node lymphocytes release a plasminogen activator. Ann. Immunol. Inst. Pasteur., 129;499–502.Google Scholar
  39. (39).
    Maillard, J.L., and Favreau, C. 1981. Plasminogen activation by normal B lymphocytes, a function associated with the cell membrane. J. Immunol., 126;1126–1130.PubMedGoogle Scholar
  40. (40).
    Fulton, R.J., and Hart, D.A. 1980. Detection and partial characterization of l3nnphoid cell surface proteases. Cell. Immunol., 55:394–405.PubMedCrossRefGoogle Scholar
  41. (41).
    Fulton, R.J., and Hart, D.A. 1981. Characterization of a plasma-membrane associated plasminogen activator on thymocytes. Biochim. Biophys. Acta, 642;345–364.PubMedCrossRefGoogle Scholar
  42. (42).
    Goldfarb, R.H., and Quigley, J.P. 1980. Purification of plasminogen activator from Rous sarcoma virus transformed chick embryo fibroblasts treated with the tumor promoter phorbol-12-myristate-13-acetate. Biochem., 19:5463–5471.CrossRefGoogle Scholar
  43. (43).
    Umezawa, H., and Ayogi, T. 1977. Activities of proteinase inhibitors of microbial origin. Proteinases in mammalian cells and tissues, ed. A. Barrett, pp. 637–662, North Holland Biomedical Press.Google Scholar
  44. (44).
    Zimmerman, M., Quigley, J.P., Ashe, B., Dorn, C., Goldfarb, R.H., and Troll, W. 1978. Direct fluorescent assay of urokinase and plasminogen activators of normal and malignant cells; kinetics and inhibitor profiles. Proc. Natl. Acad. Sci. USA, 75:750–753.PubMedCrossRefGoogle Scholar
  45. (45).
    Lane, J.T., Lo, F., and Prasad, C. 1980. Chymostatin inhibits cellular aggregation of activated human peripheral blood lymphocytes. Life Sci., 27:451–456.PubMedCrossRefGoogle Scholar
  46. (46).
    Berke, G. 1977. Recent advances and questions in lympho- cytotoxicity. In, Regulatory mechanisms in lymphocyte activation, ed. D. O. Lucas, pp. 812–816, Academic Press, New York.Google Scholar
  47. (47).
    Frye, L.D., and Friou, G.J. 1975. Inhibition of mammalian cytotoxic cells by phosphatidylcholine and its analogue. Nature, 258:333–335.PubMedCrossRefGoogle Scholar
  48. (48).
    Hoffman, T., Hirata, F., Bougnoux, P., Fraser, B.A., Goldfarb, R.H., Herberman, R.B., and Axelrod, J. 1981. Phospholipid methylation and phospholipase A2 activation in cytotoxicity by human natural killer cells. Proc. Natl. Acad. Sci. USA, 78:3839–3843.PubMedCrossRefGoogle Scholar
  49. (49).
    Clark, R.A., and Klebanoff, S.J. 1975. Neutrophil-mediated tumor cell cytotoxicity: role of the peroxidase system. J. Exp. Med., 141:1442–1447.PubMedCrossRefGoogle Scholar
  50. (50).
    Clark, R.A., Klebanoff, S.J., Einstein, A.B., and Fefer, A. 1978. Peroxidase-H202-halide system cytotoxic effect on mammalian tumor cells. Blood, 45:161–170.Google Scholar
  51. (51).
    Nathan, C.F., Bruckner, L.H., Silverstein, S.C., and Cohn, Z.A. 1979. Extracellular cytolysis by activated macrophages and granulocytes. I. Pharmacologic triggering of effector cells and the release of hydrogen peroxide. J. Exp. Med., 149:84–99.PubMedCrossRefGoogle Scholar
  52. (52).
    Nathan, C.F., Bruckner, L.H., Silverstein, S.C., and Cohn, Z. 1979. Extracellular cytolysis by activated macrophages and granulocytes. II. Hydrogen peroxide as a mediator of cytotoxicity. J. Exp. Med., 149:100–113.PubMedCrossRefGoogle Scholar
  53. (53).
    Nathan, C., and Cohn, Z. 1980. Role of oxygen dependent mechanisms in antibody-induced lysis of tumor cells by activated macrophages. J. Exp. Med., 152:198–208.PubMedCrossRefGoogle Scholar
  54. (54).
    Nathan, C., Bruckner, L., Kaplan, G., Unkeless, J.C., and Cohn, Z. 1980. Role of activated macrophages in antibody- dependent lysis of tumor cells. J. Exp. Med., 152:183–197.PubMedCrossRefGoogle Scholar
  55. (55).
    Nathan, C.F., Murray, H.W., and Cohn, Z. 1980. The Macrophage as an effector cell. N. Eng. J. Med., 303:662–626.Google Scholar
  56. (56).
    Granger, G.A., Hiserodt, J.C., and Ware, C.F. 1979. Cytotoxic and growth inhibitory lymphokines, ed. S. Cohn, E. Pick, and J. P. Oppenheim, pp. 141–163, Academic Press, New York.Google Scholar
  57. (57).
    Ballas, Z.K., and Henney, C.S. 1979. The relationship between lymphokines and cell-mediated cytotoxicity. In, Biology of the lymphokines, ed. S. Cohen, E. Pick, and J. Oppenheim, pp. 165–180, Academic Press, New York.Google Scholar
  58. (58).
    Bonnard, G., and West, W. 1979. Cell mediated cytotoxicity in humans. A critical review of experimental models and clinically oriented studies. In, Immunodiagnosis of Cancer, Part 2, ed. R. B. Herberman and K. R. Mclntire, pp. 1032–1105. Marcel Dekker, Inc., New York.Google Scholar
  59. (59).
    Peter, H.H., Eife, R.E., and Kalden, J.R. 1976. Spontaneous cytotoxicity (SCMC) of normal human lymphocytes against a human melanoma cell line: a phenomenon due to a lymphotoxin- like mediator. J. Immunol., 116:342–348.PubMedGoogle Scholar
  60. (60).
    Evans, C.H. 1981. The role of lymphotoxin in natural cell- mediated cytotoxicity. Cell Immunol., 63:1–15.PubMedCrossRefGoogle Scholar
  61. (61).
    Van Den Bosch, H. 1980. Intracellular phospholipases A. Biochim. Biophys. Acta, 604:191–246.PubMedGoogle Scholar
  62. (62).
    Rittenhouse-Simmons, S. 1981. Differential activation of platelet phospholipases by thrombin and ionophore A23187. J. Biol. Chem., 256:4153–4155.PubMedGoogle Scholar
  63. (63).
    Goldstein, B.D., Witz, G., Amoruso, M., and Troll, W. 1979. Protease inhibitors antagonize the activation of polymorphonuclear leukocyte oxygen consumption. Biochem. Biophy. Res. Comm., 88:854–860.CrossRefGoogle Scholar
  64. (64).
    Kitagawa, S., Takaku, F., and Sakamoto, S. 1979. Serine protease inhibitors inhibit superoxide production by human polymorphonuclear leukocytes and monocytes stimulated by various surface active agents. FEBS Letters, 107:331–334.PubMedCrossRefGoogle Scholar
  65. (65).
    Kitagawa, S., Takaku, F., and Sakamoto, S. 1980. Evidence that proteases are involved in superoxide producion by human polymorphonuclear leukocytes and monocytes. J. Clin. Invest., 65: 74–81.PubMedCrossRefGoogle Scholar
  66. (66).
    Weitzen, M., and Granger, G.A. 1980. The human L.T. system. VIII. A target cell dependent enzymatic activation step required for the expression of the cytotoxic activity of human lymphotoxin. J. Immunol., 125;719–724.PubMedGoogle Scholar
  67. (67).
    Kobayashi, Y., Sawada, J., and Osawa, T. 1979. Activation of membrane phospholipase A by guinea pig lymphotoxin (GLT). J. Immunol., 122:791–794.PubMedGoogle Scholar
  68. (68).
    Temple, A., and Allison, A.C. 1980. Cytolysis of fibroblasts by C3a. Brit. J. Cancer, 42:21–25.CrossRefGoogle Scholar
  69. (69).
    Granger, D.L., Taintor, R.R., Cook, J.L., and Hibbs, J.B. 1980. Injury of neoplastic cells by murine macrophages leads to inhibition of mitochondrial respiration. J. Clin. Invest., 65:357–370.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Ronald H. Goldfarb
    • 1
  • Tuomo Timonen
    • 2
  • Ronald B. Herberman
    • 2
  1. 1.Cancer Metastasis Research Group, Department of Immunology and Infectious DiseasePfizer Central ResearchGrotonUSA
  2. 2.Laboratory of Immunodiagnosis, National Cancer InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations